CJC & IPA: Composition and the important DAC distinction

Describing two components separately

Ipamorelin was experimentally characterized as a growth hormone secretagogue. The paper reports pharmacological experiments and receptor comparisons for the individual molecule. It does not investigate the finished 5 mg/5 mg blend offered here. [1]

Why “without DAC” matters

The frequently cited CJC-1295 study in healthy adults investigates a long-acting GHRH analogue approach. Its findings cannot be transferred unchanged to the version without DAC. In particular, identical persistence or time-course curves cannot be inferred. [2]

10 mg is the sum

The catalogue’s 10 mg means 5 mg plus 5 mg, rather than 10 mg of each component. The vial is a finished blend; the pen is the pre-filled format of the same compound combination. Total amount, mixing ratio and volume must be read separately.

Analytically assessing mixtures

A blend requires consideration of both component identities, their individual contents and formulation stability. Total content or a study of one component does not establish these properties. Relevant batch and formulation documentation remain authoritative.

Sources & context

1. Ipamorelin: experimental pharmacological characterization (1998)
2. Long-acting CJC-1295 in healthy adults (2006)

Sources concern the models and preparations investigated, rather than a particular shop batch. Research products are intended exclusively for laboratory research, not for human use.